Follow the link to read the full article

BCI Pharma and Mithra will start a collaboration to deliver new therapy for women! Mithra acquires the rights relating to our development program on innovative inhibitors of CSF1R kinase indicated for the treatment of female cancers and endometriosis. Press release

GSO congrès

BCI Pharma will present its promising research program targeting tumor-associated macrophages. Mode of action and efficacy data of our preclinical candidate will be discussed.

Bio-Europe 2020

BCI Pharma will discuss with pharmas and investors on their promising research projects.

BCI Pharma is delighted to communicate that the company has received a grant from the DG06 (Belgium) to financially support its second research programm.

BCI Pharma is proud to announce that Didier Malherbe accepted his nomination as board chairman. Didier will reinforced BCI structure, participated to BCI development phase and connected to more pharma experts.

bio-europe 2019

BCI Pharma will attend great strategic discussions on its neuropathic pain project.

BCI Pharma has been invited to give a lecture during the pain session at the EFMC symposium in Krakow (Poland). Great in-vivo efficacy data will be presented.

BCI Pharma will participate at the 7th International Congress on Neuropathic pain in London (United Kingdom) and will be presented their research programs on this field.

BCI Pharma is proud to announce that the company set up a scientific advisor board with experts in neuropathic pain (G. Skouteris and F. Bernhard) and translational function (M. Martiens – Toxicology, G. Mueller – Kinase research).